Brian Johnston 332-895-3222 [email protected] SOURCE TransMedics Group, Inc. TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the tr ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades. Eve ...

TransMedics (TMDX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this medical technology company have returned +50.5% over the past month versus the Zacks S&P 500 composite's -1.6% change. The Zacks Medical - Instruments industry, to which TransMedics belongs, has lost 2.5% over this period. Now the key question is: Where could the stock be headed in the near term?Wh ...

FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Commission File Number: 001-38891 TransMedics Group, Inc. (Exact name of registrant as specified in its charter) Massachusetts 83-2181531 (State or other jur ...

Financial Data and Key Metrics Changes - For Q1 2024, total revenue reached $96.9 million, marking a 133% increase from Q1 2023 and a 19% sequential increase from Q4 2023 [3][15][23] - The company achieved a GAAP operating profit of $12.4 million, representing 13% of total revenue, compared to an operating loss of $2.6 million in Q1 2023 [4][30] - Net income for the quarter was $12.2 million, a significant turnaround from the net loss of $2.6 million in the same quarter last year [4][30] - Basic earnings per share were $0.37, and diluted earnings per share were $0.35 [5] Business Line Data and Key Metrics Changes - Product revenue was $61.3 million, while service revenue was $35.5 million, with service revenue accounting for 36.7% of total revenue [25][30] - TransMedics logistics service revenue for Q1 was $14.5 million, up from $9.2 million in Q4 2023, representing approximately 58% growth quarter-over-quarter [29] - The gross margin for Q1 2024 was 62%, down from 69% in Q1 2023 but up from 59% in Q4 2023 [26][30] Market Data and Key Metrics Changes - U.S. revenue was $91.9 million, a 145% increase from Q1 2023 and a 22% sequential increase from Q4 2023 [40] - The breakdown of U.S. revenue included $67 million from liver, $20.2 million from heart, and $4.7 million from lung, all showing substantial growth [40] - Ex-U.S. revenue was $4.1 million, a 1% increase from Q1 2023 and a 16% sequential increase from Q4 2023 [40] Company Strategy and Development Direction - The company is focused on three verticals: expanding its aviation fleet and transplant logistics infrastructure, launching new clinical programs for OCS lung and heart, and increasing national transplant volumes through the NOP program [11][14][39] - Plans include targeting a minimum of 12 to 24 hours of OCS lung perfusion and developing a new lower-cost product for OCS heart cold oxygenated perfusion [2][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong momentum achieved in Q1 and emphasized the importance of clinical outcomes in driving growth [47][48] - The company updated its annual revenue guidance to a range of $390 million to $400 million, representing 61% to 66% growth over full year 2023 [6][23] Other Important Information - Total cash at the end of Q1 was $350.2 million, down $44.6 million from the end of Q4 2023, with $39 million used to purchase additional jets [5] - The company aims to cover 80% of total NOP missions using its logistics services for both air and ground transport [18] Q&A Session Summary Question: What drove the strong performance in Q1? - Management highlighted improved clinical outcomes and the growth in logistics business as key factors driving performance [47][48] Question: How should investors think about seasonal trends? - Management expects modest growth quarter-over-quarter and does not anticipate a down quarter sequentially [50] Question: What are the plans for the OCS system regarding DCD donors? - The company aims to leverage the OCS system to increase the utilization of DCD donors over the next 12 to 24 months [52] Question: What is the expected growth in the aviation segment? - Management indicated that achieving 80% coverage of U.S. cases would require approximately 25 to 30 planes [66] Question: What feedback has been received from customers using TransMedics aviation? - Customers have noted the efficiency and cost-effectiveness of TransMedics logistics services, with a growing number of programs utilizing these services [87][89]

TransMedics (TMDX) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of a loss of $0.05 per share. This compares to loss of $0.08 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 800%. A quarter ago, it was expected that this medical technology company would post a loss of $0.08 per share when it actually produced earnings of $0.12, delivering a surprise of 250%.Over the last four quarter ...

Exhibit 99.1 TransMedics Reports First Quarter 2024 Financial Results Andover, Mass. – April 30, 2024 – TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2024. Recent Highlights "We are pleased with our first quarter results as we simultaneously drove continued revenue growth, expanded our infrastructure, ...

Wall Street analysts expect TransMedics (TMDX) to post quarterly loss of $0.05 per share in its upcoming report, which indicates a year-over-year increase of 37.5%. Revenues are expected to be $83.32 million, up 100.5% from the year-ago quarter.The current level reflects an upward revision of 32.2% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Prior to a compa ...

The most recent trading session ended with TransMedics (TMDX) standing at $88.88, reflecting a -1.9% shift from the previouse trading day's closing. The stock's performance was behind the S&P 500's daily gain of 0.02%. Meanwhile, the Dow experienced a drop of 0.11%, and the technology-dominated Nasdaq saw an increase of 0.1%.Prior to today's trading, shares of the medical technology company had gained 21.63% over the past month. This has outpaced the Medical sector's loss of 4.52% and the S&P 500's loss of ...

TransMedics (TMDX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on April 30. O ...